In P02 and P43, EGFR TKI was administrated and concurrent‐resistant mutation EGFR T790M was detected with KDD in tumor tissue or plasma after the patients progressed on the treatment, suggesting KDD was unlikely to be the cause of drug resistance in P02 and P43. Here, EGFR is linked to neoplasm.